Tags

Type your tag names separated by a space and hit enter

[Obesity: a review of currently used antiobesity drugs and new compounds in clinical development].
Postepy Hig Med Dosw (Online). 2007 Oct 19; 61:612-26.PH

Abstract

This review summarizes data on currently used antiobesity drugs and new compounds under clinical development. Three antiobesity drugs are currently accepted for long-term use. Sibutramine is a noradrenaline and serotonin reuptake inhibitor which reduces body weight by about 4-5 kg but increases heart rate and arterial blood pressure. Orlistat is a gastrointestinal lipase inhibitor which results in mean weight loss by about 3 kg and reduces the incidence of type 2 diabetes in patients with impaired glucose tolerance; however, adverse gastrointestinal effects have been observed. Rimonabant is an endocannabinoid CB1 receptor antagonist which induces a 4-5 kg mean weight loss and improves glycemic and lipid profiles, but it induces anxiety and depressive disorders. Unfortunately, there are no data on the chronic administration of these drugs. Other drugs can induce weight loss, e.g. some antidepressants, antiseizure agents, and antidiabetic drugs. The moderate efficacy of currently used antiobesity drugs has led to an intense effort to identify new, safe antiobesity drugs with better therapeutic profiles. The new antiobesity drugs under clinical development include: 1) agents that affect neurotransmitters in the central nervous system, including noradrenaline and dopamine reuptake inhibitors (bupropion, radafaxine), selective 5HT2C receptor agonists (lorcaserin), and selective 5HT6 receptor antagonists, 2) agents that modulate the activity of neuropeptides influencing food intake, including leptin analogues, human ciliary neurotrophic factor (Axokine), neuropeptide Y antagonists, and melanine-concentrating hormone antagonists, 3) agents that affect the peripheral satiety signals and brain-gut axis, e.g. selective cholecystokinin receptor A agonists, PYY3-36, agents decreasing ghrelin activity, 4) thermogenic agents, e.g. selective beta3 receptor agonists and selective thyroid hormone receptor beta agonists, and 5) others, e.g. human growth hormone fragment (AOD9604) and gastrointestinal lipase inhibitor (cetilistat).

Authors+Show Affiliations

Zakład Farmakodynamiki, Uniwersytet Medyczny w Łodzi, Łódź. remusz@wp.pl

Pub Type(s)

Journal Article
Review

Language

pol

PubMed ID

17971763

Citation

Zieba, Remigiusz. "[Obesity: a Review of Currently Used Antiobesity Drugs and New Compounds in Clinical Development]." Postepy Higieny I Medycyny Doswiadczalnej (Online), vol. 61, 2007, pp. 612-26.
Zieba R. [Obesity: a review of currently used antiobesity drugs and new compounds in clinical development]. Postepy Hig Med Dosw (Online). 2007;61:612-26.
Zieba, R. (2007). [Obesity: a review of currently used antiobesity drugs and new compounds in clinical development]. Postepy Higieny I Medycyny Doswiadczalnej (Online), 61, 612-26.
Zieba R. [Obesity: a Review of Currently Used Antiobesity Drugs and New Compounds in Clinical Development]. Postepy Hig Med Dosw (Online). 2007 Oct 19;61:612-26. PubMed PMID: 17971763.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Obesity: a review of currently used antiobesity drugs and new compounds in clinical development]. A1 - Zieba,Remigiusz, Y1 - 2007/10/19/ PY - 2007/05/16/received PY - 2007/09/28/accepted PY - 2007/11/1/pubmed PY - 2008/2/5/medline PY - 2007/11/1/entrez SP - 612 EP - 26 JF - Postepy higieny i medycyny doswiadczalnej (Online) JO - Postepy Hig Med Dosw (Online) VL - 61 N2 - This review summarizes data on currently used antiobesity drugs and new compounds under clinical development. Three antiobesity drugs are currently accepted for long-term use. Sibutramine is a noradrenaline and serotonin reuptake inhibitor which reduces body weight by about 4-5 kg but increases heart rate and arterial blood pressure. Orlistat is a gastrointestinal lipase inhibitor which results in mean weight loss by about 3 kg and reduces the incidence of type 2 diabetes in patients with impaired glucose tolerance; however, adverse gastrointestinal effects have been observed. Rimonabant is an endocannabinoid CB1 receptor antagonist which induces a 4-5 kg mean weight loss and improves glycemic and lipid profiles, but it induces anxiety and depressive disorders. Unfortunately, there are no data on the chronic administration of these drugs. Other drugs can induce weight loss, e.g. some antidepressants, antiseizure agents, and antidiabetic drugs. The moderate efficacy of currently used antiobesity drugs has led to an intense effort to identify new, safe antiobesity drugs with better therapeutic profiles. The new antiobesity drugs under clinical development include: 1) agents that affect neurotransmitters in the central nervous system, including noradrenaline and dopamine reuptake inhibitors (bupropion, radafaxine), selective 5HT2C receptor agonists (lorcaserin), and selective 5HT6 receptor antagonists, 2) agents that modulate the activity of neuropeptides influencing food intake, including leptin analogues, human ciliary neurotrophic factor (Axokine), neuropeptide Y antagonists, and melanine-concentrating hormone antagonists, 3) agents that affect the peripheral satiety signals and brain-gut axis, e.g. selective cholecystokinin receptor A agonists, PYY3-36, agents decreasing ghrelin activity, 4) thermogenic agents, e.g. selective beta3 receptor agonists and selective thyroid hormone receptor beta agonists, and 5) others, e.g. human growth hormone fragment (AOD9604) and gastrointestinal lipase inhibitor (cetilistat). SN - 1732-2693 UR - https://www.unboundmedicine.com/medline/citation/17971763/[Obesity:_a_review_of_currently_used_antiobesity_drugs_and_new_compounds_in_clinical_development]_ L2 - http://www.phmd.pl/fulltxt.php?ICID=510959 DB - PRIME DP - Unbound Medicine ER -